How Pharma Can Thrive in an Analytics-Enabled Healthcare World

Posted by Dharmendra Sahay on Mon, Dec 11, 2017

Rohan Fernando co-wrote this blog post with Dharmendra Sahay.

Through data and analytics, healthcare is on the verge of a transformation, one that will change the way that providers, payers and pharmaceutical manufacturers help people manage wellness. The various players in today’s healthcare ecosystem are racing time—and each other—to collect and control patient information, all in the name of making quicker, more effective decisions and optimizing outcomes.


>
Read More

As the Goalposts Keep Moving, Pharma Can Help Providers Continue to Move the Ball Forward

Posted by Paul Darling on Mon, Nov 20, 2017

As stakeholders throughout the healthcare ecosystem continue to transition from a fee-for-service model toward value-based care—and as providers try to keep up while feeling increasingly burdened by paperwork and disconnected from patients—the Centers for Medicare & Medicaid Services (CMS) keeps moving the goalposts.


>
Read More

Healthcare’s Misalignment Means Missed Opportunities for All Stakeholders

Posted by Pratap Khedkar on Mon, Nov 13, 2017

Bill Coyle co-authored this blog post with Pratap Khedkar.

The wheels of a car in need of an alignment point in different directions and effectively begin working against each other. As a result, the vehicle works inefficiently, which negatively impacts the driver’s experience and increases the financial pain he feels at the pump. If the problem is ignored for too long, his ability to safely operate the vehicle can become compromised. And when the car is operating at a high speed, the misaligned tires could have devastating consequences, making steering difficult and potentially leading to a crash.


>
Read More

Taking the Long View on Pharma’s Reputation Management

Posted by Pratap Khedkar on Tue, Aug 08, 2017

This is the second post in a two-part series on reputation management in the pharmaceutical industry. 

I concluded my last post by saying that the actions of one company can affect the public’s perceptions of many. That, in a nutshell, is a primary contributor to the pharmaceutical industry’s reputation problem. Over the past year, for example, a few companies’ drastic drug price increases have shaped the public’s perceptions of pharmaceutical pricing overall—so much so that, in an attempt to counteract negative perceptions, many pharma companies have publicly announced plans to keep their own price increases reined in. Last October, Allergan CEO Brent Saunders promised to avoid any price increases greater than 10% per year, and a half dozen or so companies followed suit. 


>
Read More

Reputation Is Paramount, So What’s Holding Pharma Companies Back?

Posted by Pratap Khedkar on Tue, Aug 01, 2017

This is the first post in a two-part series on reputation management in the pharmaceutical industry.

Recent polls and surveys demonstrate that the pharmaceutical industry’s reputation continues to be plagued by negative perceptions. While there have been some signs of improvement here and there over the past few years, many consumers still consider pharma’s reputation to be on par with the tobacco industry, positioning one product category that treats cancer just above a product category that causes it. A survey released in March 2017 by PatientView, a U.K.-based organization that researches patient groups globally, revealed that the drug industry’s reputation took a hit in 2016 following a five-year period of progress.


>
Read More